share_log

HC Wainwright & Co. Reiterates Buy on Talaris Therapeutics, Maintains $12 Price Target

HC Wainwright & Co. Reiterates Buy on Talaris Therapeutics, Maintains $12 Price Target

HC Wainwright & Co.重申买入Talaris Therapeutics,维持12美元的目标价格
Benzinga Real-time News ·  2023/01/30 06:12

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Talaris Therapeutics (NASDAQ:TALS) with a Buy and maintains $12 price target.

HC Wainwright&Co.分析师Raghuram Selvaraju重申塔拉里斯治疗公司(纳斯达克:TALS)的买入,并维持12美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发